Biotech Values

[RockRat]

Is Herper trying to pool the efficacy results from BLOOM & BLOSSOM? Even then the efficacy number of 3% looks low. And he's definitely wrong about lorca only hitting one receptor subtype. Although it hits the A subtype 18 times less, there is enough drug to hit it a bit, and that could be responsible for what adverse effects there are, since they are what one would expect with hitting subtype A. And Herper's written about this several times, hasn't he? How long does it take for him to get it right?

Anyway, I agree there should be a REMS. Even if the panel wants a pretty restrictive REMS, if they recommend lorca, ARNA will take off, at least somewhat. About $10, say. It's hard to tell what it is priced for now, the event is so binary. But a low odds outcome would be a thumbs up without a recommendation for a REMS. Whether or not the FDA eventually signs off on that, ARNA would immediately hop well into the teens, IMO, before the shorts get a grip on it.

Regards, RockRat